These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26159503)

  • 1. Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England.
    Saxena S; Atchison C; Cecil E; Sharland M; Koshy E; Bottle A
    J Infect; 2015 Oct; 71(4):428-36. PubMed ID: 26159503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in empyema among U.S. children in the pneumococcal conjugate vaccine era.
    Wiese AD; Griffin MR; Zhu Y; Mitchel EF; Grijalva CG
    Vaccine; 2016 Dec; 34(50):6243-6249. PubMed ID: 27832918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
    Tsakir C; Özdemir H; Arga G; Konca HK; Çakmak Taşkın E; Öcal D; Çiftçi E; İnce E
    Mikrobiyol Bul; 2022 Jul; 56(3):466-479. PubMed ID: 35960238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008.
    Koshy E; Murray J; Bottle A; Sharland M; Saxena S
    Thorax; 2010 Sep; 65(9):770-4. PubMed ID: 20805169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sinusitis and pneumonia hospitalization after introduction of pneumococcal conjugate vaccine.
    Lindstrand A; Bennet R; Galanis I; Blennow M; Ask LS; Dennison SH; Rinder MR; Eriksson M; Henriques-Normark B; Ortqvist A; Alfvén T
    Pediatrics; 2014 Dec; 134(6):e1528-36. PubMed ID: 25384486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis.
    Simonsen L; Taylor RJ; Schuck-Paim C; Lustig R; Haber M; Klugman KP
    Lancet Respir Med; 2014 May; 2(5):387-94. PubMed ID: 24815804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
    Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
    Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.
    Syrogiannopoulos GA; Michoula AN; Tsimitselis G; Vassiou K; Chryssanthopoulou DC; Grivea IN
    Infect Dis (Lond); 2016 Oct; 48(10):749-53. PubMed ID: 27320108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.
    Lepoutre A; Varon E; Georges S; Dorléans F; Janoir C; Gutmann L; Lévy-Bruhl D; ;
    Vaccine; 2015 Jan; 33(2):359-66. PubMed ID: 25448105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
    Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
    Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.
    Picazo J; Ruiz-Contreras J; Casado-Flores J; Negreira S; García-de-Miguel MJ; Hernández-Sampelayo T; Otheo E; Méndez C;
    Clin Vaccine Immunol; 2013 Oct; 20(10):1524-30. PubMed ID: 23925887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
    Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
    Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and Serotype Distribution of Childhood Cases of Invasive Pneumococcal Disease Following Pneumococcal Conjugate Vaccination in England and Wales, 2006-2014.
    Oligbu G; Collins S; Andrews N; Sheppard CL; Fry NK; Slack MPE; Borrow R; Ladhani SN
    Clin Infect Dis; 2017 Oct; 65(7):1191-1198. PubMed ID: 29309553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
    Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
    Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pneumonia hospitalisations in Scotland following the introduction of pneumococcal conjugate vaccination in young children.
    Nair H; Watts AT; Williams LJ; Omer SB; Simpson CR; Willocks LJ; Cameron JC; Campbell H
    BMC Infect Dis; 2016 Aug; 16():390. PubMed ID: 27506837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. All-cause pneumonia in children after the introduction of pneumococcal vaccines in the United Kingdom: A population-based study.
    Lau WCY; Bielicki J; Tersigni C; Saxena S; Wong ICK; Sharland M; Hsia Y
    Pharmacoepidemiol Drug Saf; 2019 Jun; 28(6):821-829. PubMed ID: 30993835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
    Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
    Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-cause pneumonia hospitalizations in children <2 years old in sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction.
    Berglund A; Ekelund M; Fletcher MA; Nyman L
    PLoS One; 2014; 9(11):e112211. PubMed ID: 25379659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Towards the 13-valent pneumococcal conjugate universal vaccination: effectiveness in the transition era between PCV7 and PCV13 in Italy, 2010-2013.
    Martinelli D; Pedalino B; Cappelli MG; Caputi G; Sallustio A; Fortunato F; Tafuri S; Cozza V; Germinario C; Chironna M; Prato R;
    Hum Vaccin Immunother; 2014; 10(1):33-9. PubMed ID: 24096297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Has the incidence of empyema in Scottish children continued to increase beyond 2005?
    Nath S; Thomas M; Spencer D; Turner S
    Arch Dis Child; 2015 Mar; 100(3):255-8. PubMed ID: 25260518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.